And the conversion of CHK1'role mainly depends on ER/PR status which determines that CHK1 inhibition is a sensitizer for ADR toxicity in ER-/PR-/HER2- breast cancer and an independent damage factor in ER+/PR+/HER2- breast cancer. Here, CHEK1 is linked to breast carcinoma.